Rocket Pharmaceuticals, Inc. (RCKT)

NASDAQ: RCKT · IEX Real-Time Price · USD
19.88
+1.49 (8.10%)
At close: Dec 2, 2022 4:00 PM
20.45
+0.57 (2.87%)
After-hours: Dec 2, 2022 6:19 PM EST
8.1%
Market Cap 1.39B
Revenue (ttm) n/a
Net Income (ttm) -199.39M
Shares Out 66.22M
EPS (ttm) -2.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 942,946
Open 18.08
Previous Close 18.39
Day's Range 17.89 - 20.1
52-Week Range 7.57 - 25.62
Beta 1.27
Analysts Buy
Price Target 53.67 (+170.0%)
Earnings Date Nov 2, 2022

About RCKT

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell ... [Read more]

Industry Biotechnology
CEO Gaurav Shah
Employees 151
Stock Exchange NASDAQ
Ticker Symbol RCKT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 21 analysts, the average rating for RCKT stock is "Buy." The 12-month stock price forecast is 53.67, which is an increase of 169.97% from the latest price.

Price Target
$53.67
(169.97% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Rocket Pharmaceuticals Completes Acquisition of Renovacor

CRANBURY, N.J.--( BUSINESS WIRE )--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare ...

2 days ago - Business Wire

Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

CRANBURY, N.J.--( BUSINESS WIRE )--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare ...

1 week ago - Business Wire

RENOVACOR INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of...

NEW ORLEANS , Nov. 3, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

1 month ago - PRNewsWire

Wall Street Analysts See an 184% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?

The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to an 183.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

1 month ago - Zacks Investment Research

Does Rocket Pharmaceuticals (RCKT) Have the Potential to Rally 212% as Wall Street Analysts Expect?

The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to a 211.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

1 month ago - Zacks Investment Research

Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare ch...

1 month ago - Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STOR, RCKT, RCOR, FCRD

NEW YORK , Oct. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of...

Other symbols: FCRDSTOR
1 month ago - PRNewsWire

Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic thera...

1 month ago - Business Wire

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic thera...

2 months ago - Business Wire

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Hea...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic thera...

2 months ago - Business Wire

Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies f...

2 months ago - Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, STOR, RCKT

NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

Other symbols: EQMTCRSTOR
2 months ago - PRNewsWire

SHAREHOLDER ALERT: Weiss Law Investigates Renovacor, Inc.

NEW YORK , Sept. 20, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Renovacor, Inc. ("Renovacor" or the "Com...

2 months ago - PRNewsWire

RCKT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Rocket Pharmaceuticals, Inc. Is Fair to Sha...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) and Renovacor, Inc. is fair to Rocket shareho...

2 months ago - Business Wire

Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

CRANBURY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of ...

2 months ago - Business Wire

Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Soci...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies f...

2 months ago - Business Wire

Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies f...

2 months ago - Business Wire

Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies f...

3 months ago - Business Wire

7 Cheap Biotech Stocks to Buy Now

Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.

4 months ago - InvestorPlace

Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies f...

4 months ago - Business Wire

Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies f...

4 months ago - Business Wire

Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25t...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies f...

6 months ago - Business Wire